|
|
Antisense and
Apo B Synthesis Inhibition
|
|
|
|
Content
|
|
|
|
Apo B-100: Long-recognized as a Promising Target
|
|
|
|
Antisense Technology Provided a Method for Targeting Apo B
|
|
|
|
Antisense Drug Discovery Selectively Targets
|
|
|
|
Mipomersen – A 2nd Generation Antisense Drug
|
|
|
|
Mipomersen Crosses the Hepatocyte and Nuclear Membrane
|
|
|
|
Mechanism of Action RNase H-mediated Degradation of Target mRNA
|
|
|
|
Metabolism of Mipomersen Drug Metabolism and Disposition
|
|
|
|
Targeting Apo B Production Reduces Formation of VLDL
|
|
|
|
The Development of Mipomersen
|
|
|
|
Reductions in Total Cholesterol Correlate With Apo B mRNA in
|
|
|
|
Pharmacology Proof of Concept ApoB Inhibition
|
|
|
|
Phase 2: Hypercholesterolemia, Monotherapy
|
|
|
|
Mipomersen Significantly Reduced LDL-C in Statin-Intolerant Patients
|
|
|
|
Mipomersen Pharmacokinetic and Pharmacodynamic Properties
|
|
|
|
Mipomersen Summary of Phase 3 Clinical Studies
|
|
|
|
Phase 3 Extension Study
|
|
|
|
Phase 3 Extension Study Study Design
|
|
|
|
Phase 3 Extension Study Sustained Reduction of Atherogenic
|
|
|
|
|
|
Phase 3 Extension Study Safety Data
|
|
|
|
|
|
|
|
|
Phase 3 Extension Study Safety Summary
|
|
|
|
Phase 3 Long Term Extension Study Overall Summary
|
|
|
|
Emerging Therapies in Development
|
|
